For Families Facing Advanced Pancreatic Cancer, an Approved New Drug Doubles Remaining Time Together
The FDA has approved daraxonrasib, an insurance-covered therapy shown to double survival time for patients with advanced pancreatic cancer whose tumors resisted chemotherapy. By giving patients viable treatment when standard options fail, the medicine offers families precious extra time against one of oncology's most unforgiving diseases. While not a cure, its immediate regulatory approval ensures swift access for those in urgent need.
Source: Good News Network
Read the original story →